DK2656854T3 - Anvendelser af et aromatisk-kationisk peptid - Google Patents

Anvendelser af et aromatisk-kationisk peptid Download PDF

Info

Publication number
DK2656854T3
DK2656854T3 DK13178043.9T DK13178043T DK2656854T3 DK 2656854 T3 DK2656854 T3 DK 2656854T3 DK 13178043 T DK13178043 T DK 13178043T DK 2656854 T3 DK2656854 T3 DK 2656854T3
Authority
DK
Denmark
Prior art keywords
peptide
dmt1
dalda
mitochondria
mitochondrial
Prior art date
Application number
DK13178043.9T
Other languages
English (en)
Inventor
Hazel H Szeto
Kesheng Zhao
Peter W Schiller
Original Assignee
Cornell Res Foundation Inc
Clinical Res Inst Of Montreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc, Clinical Res Inst Of Montreal filed Critical Cornell Res Foundation Inc
Application granted granted Critical
Publication of DK2656854T3 publication Critical patent/DK2656854T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)

Claims (12)

1. Et aromatisk-kationisk peptid til anvendelse ved forøgelse af kardial, kontraktil kraft i kardialt væv, der udsættes for eller genoprettes fra iskæmi i et individ med behov derfor, hvor det aromatisk-kationiske peptid har formlen D-Arg-2'6'-Dmt-Lys-Phe-NH2.
2. Peptidet til anvendelse ifølge krav 1, hvor peptidet anvendes sammen med reperfusion af iskæmisk kardialt væv.
3. Peptidet til anvendelse ifølge krav 2, hvor reperfusionen af iskæmisk kardialt væv omfatter angioplastik, koronar bypass-operation, eller anvendelse af trombolytiske lægemidler.
4. Peptidet til anvendelse ifølge krav 2, hvor peptidet påføres koronar-stenter.
5. Peptidet til anvendelse ifølge krav 1, hvor peptidet indgives lokalt eller systemisk.
6. Peptidet til anvendelse ifølge krav 5, hvor peptidet indgives intravenøst, oralt, topisk, intranasalt, intramuskulært, subkutant, transdermalt eller iontoforetisk.
7. Et aromatisk-kationisk peptid til anvendelse ved inhibering af kardial bedøvelse af kardialt væv, der udsættes for eller genoprettes fra iskæmi i et individ med behov derfor, hvor det aromatisk-kationiske peptid har formlen D-Arg-2'6'-DMT-Lys-Phe-NH2.
8. Peptidet til anvendelse ifølge krav 7, hvor peptidet anvendes sammen med reperfusion af iskæmisk kardialt væv.
9. Peptidet til anvendelse ifølge krav 8, hvor reperfusionen af det iskæmisk kardiale væv omfatter angioplastik, koronar bypass-operation, eller anvendelse af trombolytiske lægemidler.
10. Peptidet til anvendelse ifølge krav 8, hvor peptidet påføres koronar-stenter.
11. Peptidet til anvendelse ifølge krav 7, hvor peptidet indgives lokalt eller systemisk.
12. Peptidet til anvendelse ifølge krav 7, hvor peptidet indgives intravenøst, oralt, topisk, intranasalt, intramuskulært, subkutant, transdermalt eller iontoforetisk.
DK13178043.9T 2003-02-04 2004-02-03 Anvendelser af et aromatisk-kationisk peptid DK2656854T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44477703P 2003-02-04 2003-02-04
US53569004P 2004-01-08 2004-01-08
EP04707809.2A EP1599216B9 (en) 2003-02-04 2004-02-03 Methods for preventing mitochondrial permeability transition

Publications (1)

Publication Number Publication Date
DK2656854T3 true DK2656854T3 (da) 2015-07-06

Family

ID=32853391

Family Applications (3)

Application Number Title Priority Date Filing Date
DK13178043.9T DK2656854T3 (da) 2003-02-04 2004-02-03 Anvendelser af et aromatisk-kationisk peptid
DK14186875.2T DK2865385T3 (da) 2003-02-04 2004-02-03 Anvendelser af aromatisk-kationisk peptid
DK04707809.2T DK1599216T3 (da) 2003-02-04 2004-02-03 Fremgangsmåde til forebyggelse af mitokondriel permeabilitets-transition

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK14186875.2T DK2865385T3 (da) 2003-02-04 2004-02-03 Anvendelser af aromatisk-kationisk peptid
DK04707809.2T DK1599216T3 (da) 2003-02-04 2004-02-03 Fremgangsmåde til forebyggelse af mitokondriel permeabilitets-transition

Country Status (14)

Country Link
US (8) US7576061B2 (da)
EP (9) EP3144009A1 (da)
JP (7) JP4838114B2 (da)
CN (3) CN104225574B (da)
AU (1) AU2004209663B2 (da)
CA (1) CA2515080C (da)
CY (2) CY1114959T1 (da)
DK (3) DK2656854T3 (da)
ES (3) ES2540897T3 (da)
HK (6) HK1131995A1 (da)
HU (1) HUE027110T2 (da)
PT (2) PT1599216E (da)
SI (1) SI2656854T1 (da)
WO (1) WO2004070054A2 (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3144009A1 (en) * 2003-02-04 2017-03-22 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
DK1625149T3 (da) 2003-05-01 2016-05-30 Cornell Res Foundation Inc Fremgangsmåde og bærerkomplekser til tilførsel af molekyler til celler
CA2554166C (en) * 2004-01-23 2014-07-29 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
AU2014203126B2 (en) * 2005-09-16 2016-03-10 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
JP5416971B2 (ja) 2005-09-16 2014-02-12 コーネル リサーチ ファウンデイション インコーポレイテッド Ｃｄ３６の発現を減少させる方法
CN104107417B (zh) 2008-02-07 2017-04-12 康奈尔大学 用于预防或治疗胰岛素抵抗性的方法
CN101951936A (zh) 2008-02-26 2011-01-19 康奈尔大学 用于防止和治疗急性肾损伤的方法
DE102008061044A1 (de) 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
CN102573881A (zh) 2009-03-20 2012-07-11 通用医疗公司以马萨诸塞州通用医疗公司名义经营 预防和治疗烧伤损伤和继发性并发症的方法
CN102647994A (zh) * 2009-08-12 2012-08-22 康奈尔大学 预防或治疗代谢综合症的方法
EP2470191B1 (en) * 2009-08-24 2014-05-07 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
CN102711785A (zh) * 2009-10-05 2012-10-03 康奈尔大学 预防或治疗心力衰竭的方法
WO2011082324A1 (en) * 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
JP2013516426A (ja) * 2009-12-31 2013-05-13 ステルス ペプチドズ インターナショナル インコーポレイテッド 冠状動脈バイパス移植術を行うための方法
EP2733150A1 (en) * 2010-01-25 2014-05-21 Cornell University Aromatic-cationic peptides and uses of same
JP2013521231A (ja) * 2010-02-26 2013-06-10 ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する
EP2808029A3 (en) 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US20110245182A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245183A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
JP2013532124A (ja) * 2010-05-03 2013-08-15 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族系陽イオンペプチド及びその使用
CA2804404C (en) * 2010-07-09 2020-10-20 Stealth Peptides International, Inc. Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
US20160176930A1 (en) 2010-07-09 2016-06-23 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
WO2014137496A1 (en) * 2013-03-08 2014-09-12 The Administrators Of The Tulane Educational Fund Mu opioid receptor agonist analogs of the endomorphins
US20120083452A1 (en) * 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
EP2688579A4 (en) * 2011-03-24 2015-10-21 Univ Cornell AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
JP2014527969A (ja) * 2011-09-19 2014-10-23 ジェンシア コーポレイション 改変クレアチン化合物
JP6157481B2 (ja) 2011-09-29 2017-07-05 メイヨ ファンデーション フォア メディカル エディケイション アンド リサーチ 芳香族陽イオン性ペプチドおよびその使用方法
WO2013059071A1 (en) * 2011-10-17 2013-04-25 Cornell University Aromatic-cationic peptides and uses of same
EP3466439A1 (en) * 2011-12-09 2019-04-10 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
WO2013149172A1 (en) * 2012-03-30 2013-10-03 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
JP2015529655A (ja) * 2012-08-02 2015-10-08 ステルス ペプチドズ インターナショナル インコーポレイテッド アテローム性硬化症の処置方法
JP2016503397A (ja) * 2012-10-22 2016-02-04 ステルス ペプチドズ インターナショナル インコーポレイテッド 心不全関連リスクおよびそれらと関連する因子を減少させる方法
DK2961420T3 (da) * 2013-03-01 2019-10-07 Stealth Biotherapeutics Corp Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom
CN105517533A (zh) 2013-03-01 2016-04-20 康德生物医疗技术公司 治疗线粒体疾病的方法
WO2014174517A1 (en) 2013-04-25 2014-10-30 Carmel-Haifa University Economic Corp. Synthetic anti-inflammatory peptides and use thereof
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
CA2919992C (en) * 2013-08-01 2022-08-09 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
US20160166633A1 (en) 2013-08-02 2016-06-16 Stealth Bio Therapeutics Corp Methods and compositions for the prevention and treatment of friedreich's ataxia
JP6434523B2 (ja) * 2013-09-30 2018-12-05 コーネル ユニヴァーシティー カルジオリピン標的化ペプチドはベータアミロイドオリゴマー毒性を阻害する
WO2015192020A1 (en) 2014-06-13 2015-12-17 Children's Medical Center Corporation Products and methods to isolate mitochondria
PL3160984T3 (pl) 2014-06-25 2021-10-25 Flamma S.P.A. Sposób wytwarzania d-arginylo-2,6-dimetylo-l-tyrozylo-l-lizylol- fenyloalaninoamidu
SI3160985T1 (sl) 2014-06-30 2021-11-30 Flamma S.P.A. Postopek za pripravo D-arginil-2,6-dimetil-L-tirosil-L-lisil-L- fenilalaninamida
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CN104306954B (zh) * 2014-09-25 2016-08-24 中山大学 Wry三肽在制备治疗阿尔茨海默症药物中的用途
WO2016069556A2 (en) 2014-10-29 2016-05-06 University Of Maryland Methods of treating age-related symptoms in mammals and compositions therefor
WO2017015660A1 (en) * 2015-07-23 2017-01-26 Salk Institute For Biological Studies Prevention and treatment of aging and neurodegenerative diseases
CA3006698A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
WO2017156403A1 (en) * 2016-03-11 2017-09-14 Stealth Biotherapeutics Crystalline salt forms
WO2017180535A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
WO2018100893A1 (ja) 2016-11-30 2018-06-07 株式会社ダイセル 撮像装置用レンズモジュール及びその製造方法
WO2018187400A1 (en) 2017-04-05 2018-10-11 Stealth Biotherapeutics Corp. Crystalline salt forms of boc-d-arg-dmt-lys-(boc)-phe-nh2
CN111278807B (zh) 2017-08-17 2022-07-22 凯瑞康宁生物工程（武汉）有限公司 活性氧清除剂衍生物的制备及用途
CN115475229A (zh) 2017-09-04 2022-12-16 凯瑞康宁生物工程（武汉）有限公司 活性氧清除剂的制备及用途
JP6958860B2 (ja) * 2017-11-07 2021-11-02 学校法人自治医科大学 ミトコンドリアの機能障害の改善剤、及びミトコンドリアの機能障害に起因する疾患又は症状の予防又は治療薬、並びにそれらの用途
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
CA3123368A1 (en) * 2018-12-18 2020-06-25 Stealth Biotherapeutics Corp. Mitochondria-targeting peptides
US20220347212A1 (en) * 2019-05-02 2022-11-03 Children`S Medical Center Corporation Prophylactic and therapeutic use of mitochondria and combined mitochondrial agents
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
GB2614162A (en) 2020-09-09 2023-06-28 Social Profit Network Methods and compositions for delivery of biotin to mitochondria

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
EP0350221B1 (en) 1988-06-30 1996-04-17 Astra Aktiebolag Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same
US5652122A (en) 1989-12-21 1997-07-29 Frankel; Alan Nucleic acids encoding and methods of making tat-derived transport polypeptides
WO1992012722A1 (en) * 1990-01-17 1992-08-06 The Regents Of The University Of California Antifreeze glycopeptide compositions to protect cells and tissues during freezing
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
EP0747092B1 (en) * 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
DE69722258T2 (de) * 1996-10-07 2004-03-18 Eli Lilly And Co., Indianapolis Neue verbindungen nutlich als neuroschützende mittel
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
JP2002505077A (ja) 1997-12-10 2002-02-19 ワシントン大学 抗病原体システムおよびその使用方法
AU3965699A (en) * 1998-04-24 1999-11-16 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6472378B2 (en) * 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
GB9905503D0 (en) * 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
JP2003511045A (ja) * 1999-10-04 2003-03-25 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュー ジャージー Ｒｎａ結合化合物の同定方法
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
AU2001277908A1 (en) * 2000-07-18 2002-01-30 Cornell Research Foundation Inc. Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
CA2430409A1 (en) * 2000-11-28 2002-06-06 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and their use
US6545097B2 (en) * 2000-12-12 2003-04-08 Scimed Life Systems, Inc. Drug delivery compositions and medical devices containing block copolymer
EP1360173A2 (en) * 2001-01-25 2003-11-12 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
ATE434418T1 (de) * 2001-02-16 2009-07-15 Cordis Corp Verfahren zur herstellung eines ballonkatheter- stentapplikationssystems mit furchen
JP2004526499A (ja) * 2001-03-16 2004-09-02 エスティーエス バイオポリマーズ，インコーポレイティド 複数層ポリマーコーティングを有する薬物添加ステント
JPWO2002102833A1 (ja) * 2001-06-15 2004-09-30 千寿製薬株式会社 新規エンドモルフィン誘導体
CN101440124B (zh) * 2003-02-04 2012-07-18 科内尔研究基金会 用于防止线粒体通透性改变的方法
EP3144009A1 (en) * 2003-02-04 2017-03-22 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
DK1625149T3 (da) 2003-05-01 2016-05-30 Cornell Res Foundation Inc Fremgangsmåde og bærerkomplekser til tilførsel af molekyler til celler
JP2005005762A (ja) * 2003-06-09 2005-01-06 Fujitsu Ltd 送信電力制御方法及び装置
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
CA2554166C (en) * 2004-01-23 2014-07-29 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
JP5416971B2 (ja) 2005-09-16 2014-02-12 コーネル リサーチ ファウンデイション インコーポレイテッド Ｃｄ３６の発現を減少させる方法

Also Published As

Publication number Publication date
EP2865385B1 (en) 2016-11-16
HUE027110T2 (en) 2016-08-29
JP5775285B2 (ja) 2015-09-09
CN102784383A (zh) 2012-11-21
CN104225574A (zh) 2014-12-24
US20040248808A1 (en) 2004-12-09
JP2019089773A (ja) 2019-06-13
HK1209652A1 (en) 2016-04-08
US20230293624A1 (en) 2023-09-21
EP1599216B1 (en) 2013-11-06
JP2015180693A (ja) 2015-10-15
EP1599216B9 (en) 2015-02-11
EP3659618A1 (en) 2020-06-03
EP1599216A4 (en) 2009-11-11
JP4838114B2 (ja) 2011-12-14
JP6126059B2 (ja) 2017-05-10
CY1114959T1 (el) 2016-12-14
EP2491943A2 (en) 2012-08-29
HK1131995A1 (en) 2010-02-12
US20150359838A1 (en) 2015-12-17
EP3144009A1 (en) 2017-03-22
EP2491943B1 (en) 2018-10-10
PT2656854E (pt) 2015-09-03
JP5837542B2 (ja) 2015-12-24
US8404646B2 (en) 2013-03-26
JP2013249313A (ja) 2013-12-12
ES2605504T3 (es) 2017-03-14
EP3479838A1 (en) 2019-05-08
SI2656854T1 (sl) 2015-09-30
CN102617706A (zh) 2012-08-01
EP3842055A1 (en) 2021-06-30
AU2004209663A1 (en) 2004-08-19
US20100190718A1 (en) 2010-07-29
DK2865385T3 (da) 2016-12-19
US7718620B2 (en) 2010-05-18
JP6166312B2 (ja) 2017-07-19
CN104225574B (zh) 2017-01-11
CA2515080C (en) 2012-04-10
AU2004209663A2 (en) 2004-08-19
JP2011026346A (ja) 2011-02-10
ES2436011T3 (es) 2013-12-26
HK1204999A1 (en) 2015-12-11
AU2004209663B2 (en) 2009-01-15
DK1599216T3 (da) 2013-12-09
CN102784383B (zh) 2014-09-17
WO2004070054A2 (en) 2004-08-19
US20070027087A1 (en) 2007-02-01
JP2015007127A (ja) 2015-01-15
EP2865385A1 (en) 2015-04-29
US8957030B2 (en) 2015-02-17
EP2491943A3 (en) 2013-01-23
HK1090571A1 (en) 2006-12-29
CY1116575T1 (el) 2017-03-15
US20130244957A1 (en) 2013-09-19
PT1599216E (pt) 2013-12-17
ES2540897T3 (es) 2015-07-14
EP1599216A2 (en) 2005-11-30
CA2515080A1 (en) 2004-08-19
HK1190930A1 (en) 2014-07-18
EP2656854A1 (en) 2013-10-30
EP3305313A1 (en) 2018-04-11
JP2017095519A (ja) 2017-06-01
US7576061B2 (en) 2009-08-18
EP2656854B1 (en) 2015-05-20
US20120021970A1 (en) 2012-01-26
JP2006516652A (ja) 2006-07-06
WO2004070054A3 (en) 2005-04-14
US20200038472A1 (en) 2020-02-06
HK1178794A1 (en) 2013-09-19

Similar Documents

Publication Publication Date Title
DK2656854T3 (da) Anvendelser af et aromatisk-kationisk peptid
EP1931369B1 (en) Aromatic-cationic peptide for use in a method for reducing CD36 expression